ABSTRACT
Trade names: Diabeta (Sanofi-Aventis); Glucovance (Bristol-Myers Squibb); Glynase (Pfizer); Micronase (Pfizer) Other common trade names: Albert (Glyburide); Daonil; Euglucan; Euglucon; Glimel; Glucal; Hemi-Daonil; Med-Glibe; Miglucan; Norboral Indications: Non-insulin dependent diabetes type ll Category: Second generation sulfonylurea antidiabetic Half-life: 5-16 hours Clinically important, potentially hazardous interactions with: bosentan
Glucovance is glyburide and metformin
Reactions
Skin Allergic reactions (sic) (0.21%) [1] Angioedema Bullous eruption [1] Eczema Erythema (1-5%) [1] Exanthems (1-5%) [3] Exfoliative dermatitis Flushing [2] Lichenoid eruption Linear IgA dermatosis [2] Pemphigus [1] Peripheral edema [1] Photosensitivity (1-10%) [7] Pruritus (1-10%) [3] Psoriasis [2]
Purpura [2] Rash (sic) (1-10%) Urticaria (1-5%) [5] Vasculitis [5] Vesiculobullous eruption [1]
Eyes Eyelid edema [1]
Other Dysgeusia Headache Hypersensitivity (generalized) [1] Myalgia Paresthesias (<1%) Porphyria cutanea tarda
*Note: Glyburide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome
